Coronary heart disease is a common disease threatening human health. In recent years, the incidence of coronary heart disease in China has only increased. It is the most common type of organ disease caused by coronary atherosclerosis, which is observed in the aorta, carotid artery, and femoral artery. The main clinical treatments for coronary heart disease include coronary artery bypass grafting and drug treatment. To investigate the relationship of serum adipocytokine C1q/tumor necrosis factor-related protein 9 (CTRP9), amyloid A (SAA), and plasma homocysteine (Hcy) with coronary artery plaque characteristics in patients with coronary heart disease. Overall, 143 patients with coronary heart disease admitted to our hospital are selected as research participants. The proportion of plaque necrosis core volume is higher in group A than in group B, and the differences are statistically significant (P < 0.05). In group A, necrotic core volume percentage is negatively correlated with CTRP9 levels and positively correlated with SAA and Hcy levels (P < 0.05). Logistic regression analysis revealed that increased systolic blood pressure, increased number of coronary artery lesions, decreased CTRP9 levels, and increased Hcy levels are independent risk factors for thin fibrous cap atherosclerosis in patients with coronary heart disease (P < 0.05). Decreased CTRP9 levels and increased Hcy levels are independent risk factors for coronary heart disease patients with thin fibrous cap atherosclerosis.

目的 观察沙库巴曲缬沙坦治疗老年慢性心衰急性加重患者的临床效果及对NT-proBNP、hs-CRP、心功能、生活质量的影响.方法 选取吉林省一汽总医院心血管内科2019年1月～2019年11月收治的50例老年慢性心衰急性加重患者为研究对象,按照随机数表法分为试验组和对照组,每组25例.对照组患者行常规治疗,试验组患者在常规治疗基础上加服沙库巴曲缬沙坦治疗.对比两组患者的临床疗效、N末端B型利钠肽前体(NT-proBNP)、超敏C-反应蛋白(hs-CRP)、心功能指标、生活质量水平.结果 治疗后,试验组患者的临床疗效高于对照组,差异有统计学意义(P<0.05).试验组患者的心功能指标左心室射血分数(LVEF)明显高于对照组,心功能指标[左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)]及NT-proBNP和hs-CRP水平明显低于对照组,差异有统计学意义(P<0.05).试验组患者的生活质量明显高于对照组,差异有统计学意义(P<0.05).结论 沙库巴曲缬沙坦可有效促进老年慢性心衰急性加重患者的心脏功能改善,提高治疗效果,降低血清学指标水平,提高患者的生活质量.

目的 探究沙库巴曲缬沙坦钠于慢性心力衰竭治疗中临床疗效及安全性分析.方法 选择我院心内科2018年1月—2019年12月收治慢性心力衰竭患者97例为观察对象,采用数字奇偶分布方式划分小组,均予以对症治疗,48例分设参照组,联合依那普利治疗,49例分设观察组,联合沙库巴曲缬沙坦钠治疗,分析两组药物疗效及不良反应.结果 治疗后观察组左室舒张末期内径(left ventricular end-diastolic dimension,LVEDD)、左室收缩末期内径LVESD(left ventricular end systolic diameter,LVESD)指标低于参照组、左室射血分数(left ventricular ejection fractions,LVEF)、6 min步行距离指标高于参照组(P<0.05);观察组氨基末端B型利钠肽前体(brain natriuretic peptide, NT-proBNP)指标低于参照组(P<0.05);两组患者于用药期间均无严重不良反应(P>0.05).结论 慢性心力衰竭治疗中联合沙库巴曲缬沙坦钠,利于心功能恢复,促使NT-proBNP水平降低,药物不良反应机制可控,可为对症治疗增效.

目的 观察心力衰竭采用沙库巴曲缬沙坦联合β受体阻滞剂治疗的效果.方法 选取2017年10月—2019年10月收治的心力衰竭患者34例,随机数字表法进行分组,分为观察组和对照组,每组各17例,观察组给予美托洛尔+沙库巴曲缬沙坦治疗,对照组实施β受体阻滞剂美托洛尔治疗,对比治疗效果、心功能、血清指标、不良反应.结果 观察组有效率、LVEF水平均高于对照组,观察组LVESD、LVEDD、NT-proBNP、cTn I水平均低于对照组(P<0.05).结论 沙库巴曲缬沙坦联合β受体阻滞剂治疗心力衰竭效果显著,可有效改善心功能.

目的 研究并对比冠心病采用瑞舒伐他汀与阿托伐他汀治疗的效果.方法 2017年12月—2019年12月,选取我院收治的冠心病患者110例,按照随机数字表法进行分组,每组各55例,观察组给予瑞舒伐他汀治疗,对照组实施阿托伐他汀治疗,对比治疗效果、血脂、不良反应.结果 观察组有效率、高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)高于对照组,观察组不良反应发生率、总胆固醇(total cholesterol,TC)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)、甘油三脂(triglyceride,TG)均低于对照组(P＜0.05).结论 冠心病患者采用瑞舒伐他汀治疗效果显著优于阿托伐他汀,可有效降低不良反应,控制血脂水平,值得应用.

左心室室壁瘤（LVA）是指急性心肌梗死后,心脏局部室壁呈瘤样膨出于心室表面的病理改变[1],心室壁出现矛盾运动,致使心肌运动减弱或消失,从而产生心室射血分数降低的区域[2],其形成主要与局部心肌组织坏死、变薄,导致局部心肌收缩力减弱、心肌重构有关[3,4],可导致恶性室性心律失常、室间隔穿孔、心力衰竭、左心室附壁血栓等并发症,若出现心脏破裂死亡率达到100%[5,6]。LVA在急性心肌梗死存活患者中发生率为10%-38%[7],现将本院收治的1例急性心肌梗死并发巨大室壁瘤病例报道如下。

目的 观察分析胺碘酮联合稳心颗粒治疗老年室性心律失常患者的临床疗效.方法 选择我院2016年1月-2017年7月收治的老年室性心律失常患者116例,随机分为对照组和联合组,每组58例,对照组采用胺碘酮进行治疗,联合组在对照组治疗方法的基础上加用稳心颗粒进行治疗.所有患者均连续治疗1个月,比较两组的临床疗效以及治疗前后心率和P-R间期.结果 联合组总有效率高于对照组(96.55%vs.77.59%),差异具有统计学意义(P<0.05).两组治疗后心率和P-R间期均改善,且联合组改善较对照组更加显著,差异均有统计学意义(P<0.05).结论 胺碘酮联合稳心颗粒治疗老年室性心律失常患者可以取得较好的临床疗效.

Objective To regard the patients with coronary heart disease who were treated with PCI as the objects of study,the research analyzes and compares&nbsp;patients'postoperative effects by using clopidogrel and ticagrelor as wel as the potential adverse events.Methods It selects 150 patient cases with coronary heart disease who were treated with PCI in the hospital from August 2014 to August 2015,and divides them randomly into folowing two groups: the group of clopidogrel and the group of ticagrelor with the same patient number. Then it respectively analyzes and compares the clinical effects of these two medicines as wel as MACE.ResultsThe total effective rate of the clopidogrel group is 76.0%,while that of the ticagrelor group is 93.3% ,Patients with a postoperative MACE of the clopidogrel group is a total 30 cases,while that of the other group is a total 10 cases. Compare the two groups of patients in curative effects and MACE,the differences have statistical significance. (P<0.05) . Conclusion The patients with coronary heart disease who were treated with PCI wil have better curative effects when using ticagrelor,and the patients with a postoperative MACE is less.

目的 探讨围手术期高龄冠心病患者介入治疗的效果影响.方法 选择我院2014年5月～2015年4月收治的高龄冠心病患者90例作为研究对象,将其分为实验组与参照组,各45例.两组患者均行介入治疗,对两组患者的疗效、各项临床指标及并发症等情况进行观察与比较.结果两组治疗成功率比较,差异有统计学意义(P＜0.05);两组患者各项临床指标比较,差异无统计学意义(P＞0.05);两组患者并发症发生率比较,差异无统计学意义(P＞0.05).结论 对高龄冠心病患者采取经桡动脉入路介入治疗可取得良好的效果,不会使得X线曝光时间增加,并且并发症发生率较低,值得推广.